Navigation Links
Anti-tumor necrosis factor treatment does not increase cancer Risk in RA patients
Date:10/28/2009

A recent study by Swedish researchers found that rheumatoid arthritis (RA) patients did not experience an elevated cancer risk in the first 6 years after starting anti-tumor necrosis factor (TNF) therapy. The research team, led by Johan Askling, M.D., Ph.D., from Karolinska University Hospital in Stockholm, Sweden assessed the short-term and medium-term cancer risk for RA patients using anti-TNF therapies: infliximab, adalimumab, and etanercept. Details of the study appear in the November issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology published by Wiley-Blackwell.

TNF is a cytokine (substance secreted by immune system cells) that regulates the body's immune system and is involved in inflammation. TNF inhibitors (or TNF blockers) are a class of therapies used to reduce inflammation in chronic inflammation such as RA. The common immunosuppressant drugs and those included in the study are Remicade, HumiraTM, and Enbrel. As these therapies are used to treat chronic inflammatory illnesses, the long-term inhibition of TNF raises concerns for increased risk of infections and cancer.

This study, one of the largest and longest population-based assessments of cancer risks associated with immunosuppressive therapy, included data from several Swedish databases including the Biologics Register, the Cancer Register, and the Early RA Register. Researchers identified and analyzed data from 6,366 patients who started anti-TNF therapy between January 1999 and July 2006. Data from patients using TNF inhibitors was compared with other groups of RA patients61,160 not taking medication, 4015 using methotrexate (the gold standard in RA treatment) and 4,015 taking combinations of disease-modifying anti-rheumatic drugs (other than TNF inhibitors).

Results show there were 240 first primary cancers diagnosed during the 25,693 person-years of follow-up in the patients using anti-TNF therapy who had no history of cancer at the onset of immunosuppressant treatment. When compared to the larger national RA cohort who did not receive TNF inhibitors or have a history of cancer, the relative risk of anti-TNF therapy was 1.00 and remained unchanged for those taking immunosuppressant drugs for up to 6 years. "Our research indicates the overall cancer risk is the same for RA patients on immunosuppressant therapies and those not taking medications for the disease," confirmed Dr. Askling, but adds that "given several remaining uncertainties, continued vigilance remains prudent."


'/>"/>

Contact: Dawn Peters
medicalnews@wiley.com
781-388-8408
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. CD200 stifles anti-tumor immunity
2. A new light on the anti-tumor mechanisms of Scutellaria barbata
3. Mersanas Second Development Candidate, XMT-1107, Shows Superior Pharmacokinetics and Anti-Tumor Activity in Studies Presented at American Association of Cancer Research Meeting
4. Short-term stress enhances anti-tumor activity in mice, Stanford study shows
5. Massive necrosis after trans-catheter treatment is more common in the presence of tumor capsule
6. Popular osteoporosis drugs triple risk of bone necrosis
7. Link between treating osteoporosis with bisphosphonates and incidence of bone necrosis examined
8. Effect of tumor necrosis factor a inhibitors on heart failure risk in RA Patients
9. USC dentist links Fosomax-type drugs to jaw necrosis
10. Orthopedic Surgeon Dr. Marc W. Hungerford, a Leading Expert in Field of Avascular Necrosis, Now at Baltimore's Mercy Medical Center
11. Amgen and Wyeth Statement on FDA Announcement About Tumor Necrosis Factor (TNF) Blockers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... Indianapolis, IN (PRWEB) , ... April 25, 2017 ... ... Washington, D.C., CEOs, CFOs and HR decision-makers are preparing for how his administration ... Life Financial will provide insight into what changes are most likely to make ...
(Date:4/25/2017)... ... April 25, 2017 , ... As pharmaceutical companies are ... help with process innovation in drug formulation and manufacturing. CoreRx offers its ... analytical equipment in support of their development and manufacturing goals. , The ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... predictive analytics to its patient care management module. Using this new feature, sleep ... patient has been initiated on continuous positive airway pressure (CPAP), oral, or other ...
(Date:4/24/2017)... ... ... Emmanuel College is introducing enhancements to its RN-to-BSN Degree Program ... of 2017, Emmanuel’s program will allow registered nurses (RN)s to earn a Bachelor of ... little as $14,528. These changes will enable nurses to complete their degree in a ...
(Date:4/24/2017)... ... , ... As part of the nationwide Days of Remembrance effort led by ... and Nazi persecution, Center for Medicine after the Holocaust (CMATH) announced that ... to Germany and Poland next week. , The Fourth Biennial CMATH Champions Trip to ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... BOSTON , April 20, 2017   ZappRx, Inc ... the specialty drug prescribing process, today announced it closed $25 ... Fund, a venture capital firm based in Seattle ... Qiming Venture Partners . The Series B round included ... A round in 2014, and GV (formerly Google ...
(Date:4/20/2017)... Research and Markets has announced the addition of ... By Service (Manufacturing, Research), By Country, (Brazil, Mexico, Colombia, Argentina, ... to their offering. ... The Latin American pharmaceutical contract manufacturing services market is anticipated ... drug registration cost in Latin American countries and continuous economic ...
(Date:4/19/2017)... April 19, 2017 Global Surgical Drainage Device ... tubes used to remove excess liquid and air. The ... urine, bile or lymph. Surgical drains are used in ... as orthopedics surgery, cardiovascular surgery, neurosurgery, plastic surgery etc. ... to prevent accumulation of fluid e.g. blood or pus. ...
Breaking Medicine Technology: